Syngene is a contract research, development and manufacturing organization (CRDMO) that provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies.
Syngene’s clients are world leaders in their fields, ranging from leading global multinationals to small and medium-sized start-ups, non-profit institutions, academic institutes and government organizations.

Incorporated in 1993, Syngene is listed separately on the Indian stock exchanges – NSE and BSE. With a unique business model, a talent pool of 5656 scientists, scientific expertise across new therapeutic modalities, an experienced management team, and an independent Board committee, Syngene works for clients around the globe, delivering innovation that benefits human and animal health. As a strategic partner to its clients, often working as an extension of their internal scientific teams, Syngene offers innovative, flexible, and efficient approaches to scale up rapidly. This, in turn, enables faster go-to-market and access to patients.

Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational…